Drug Pricing: Page 3

  • President Biden talks about his proposed 2024 federal budget plan at an event in Philadelphia on March 9, 2023.
    Image attribution tooltip
    Chip Somodevilla/Staff via Getty Images
    Image attribution tooltip

    Biden takes fresh aim at drug prices with new budget plan

    The proposal, viewed as a “non-starter” by one analyst, seeks to double the number of drugs Medicare can negotiate prices for and open up those talks more quickly.

    By • March 10, 2023
  • U.S. President Joe Biden delivers his State of the Union address during a joint meeting of Congress in the House Chamber of the U.S. Capitol on February 07, 2023 in Washington, DC.
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Biden’s plan to extend Medicare solvency targets prescription drugs

    The proposal — part of a 2024 budget set to be released Thursday — would further reduce what Medicare pays for prescription drugs and raise taxes on Americans earning over $400,000.

    By Rebecca Pifer • March 7, 2023
  • Explore the Trendline➔
    Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip
    Trendline

    Drug pricing

    Drug pricing legislation has put pharmaceutical companies on the defensive and created a new precedent for the industry.

    By BioPharma Dive staff
  • Colorful illustrations depicting financial gain
    Image attribution tooltip
    Permission granted by Phil Inc
    Image attribution tooltip
    Sponsored by Phil

    Harnessing data to improve patient access and optimize gross-to-net

    Discover the data and metrics you should be tracking to evaluate patient access.

    March 6, 2023
  • A building with logo of drugmaker Eli Lilly.
    Image attribution tooltip
    Eli Lilly & Co.
    Image attribution tooltip

    Lilly to lower insulin prices by 70%

    The pharma company, along with its diabetes drug rivals Novo Nordisk and Sanofi, has long been under pressure over the high cost of insulin — scrutiny that has recently ramped up in the U.S.

    By • March 1, 2023
  • Colorful illustrations depicting financial gain
    Image attribution tooltip
    Permission granted by Phil Inc
    Image attribution tooltip
    Sponsored by Phil

    Harnessing data to improve patient access and optimize gross-to-net

    Discover the data and metrics you should be tracking to evaluate patient access.  

    Feb. 27, 2023
  • A vial of Eisai and Biogen's Alzheimer's disease drug Leqembi
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip

    Medicare maintains limits on Eisai’s new Alzheimer’s drug

    Eisai and Biogen have data showing Leqembi slows cognitive decline, but CMS won’t budge until FDA converts its approval from accelerated to full.

    By • Feb. 23, 2023
  • A piece of DNA stretches vertically along a plain background.
    Image attribution tooltip
    Getty / Edited by BioPharma Dive
    Image attribution tooltip

    Medicaid, with planned payment pilot, girds for influx of pricey gene therapies

    The proposed model could help state Medicaid agencies explore different kinds of outcomes-based payment schemes, but may come too late to prepare for the first sickle cell gene therapy.

    By • Feb. 21, 2023
  • An AbbVie sign is seen on the outside of a building in California.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip
    Deep Dive // Patent thickets

    Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’

    Many top-selling products will lose patent protection by the end of the decade, putting pressure on companies to replace lost revenue with new medicines.

    By • Feb. 21, 2023
  • A picture of Xavier Becerra giving a speech at a podium
    Image attribution tooltip
    Alex Wong via Getty Images
    Image attribution tooltip

    CMS plans trio of experiments aimed at lowering drug costs

    The pilot programs could allow adjusted payments for drugs cleared under accelerated approval and help states manage the costs of gene therapies.

    By • Feb. 15, 2023
  • The front of the department of health and human services building with a sign in front of the exterior building
    Image attribution tooltip
    Mark Wilson via Getty Images
    Image attribution tooltip

    Medicare to collect drug price rebates starting in 2025

    CMS laid out how it plans to implement a key provision of the Inflation Reduction Act, which requires drugmakers to pay rebates on price hikes within Medicare that are greater than inflation.

    By • Feb. 10, 2023
  • U.S. President Joe Biden delivers his State of the Union address during a joint meeting of Congress in the House Chamber of the U.S. Capitol on February 07, 2023 in Washington, DC.
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    In address to Congress, Biden touts drug pricing law and pushes insulin cost caps

    In his State of the Union speech, Biden threatened to veto any efforts to repeal the legislation and chastised drugmakers for the high cost of insulin.

    By Kristin Jensen • Feb. 8, 2023
  • An outside view of an Amgen building.
    Image attribution tooltip
    Amgen Inc.
    Image attribution tooltip

    Humira biosimilars arrive in the US, as Amgen launches first copycat to AbbVie’s blockbuster drug

    The world’s best-selling drug will face pricing pressure as rivals try to steal share from AbbVie’s $20 billion-a-year flagship product in the U.S. 

    By • Jan. 31, 2023
  • Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip

    Moderna draws more lawmaker criticism for COVID vaccine pricing plan

    Senators Warren and Welch urged the biotech to reconsider a planned price hike to between $110 and $130 a dose, and sought answers to a long list of questions.

    By Kristin Jensen • Jan. 26, 2023
  • A Pfizer sign on a building.
    Image attribution tooltip
    Jeenah Moon via Getty Images
    Image attribution tooltip

    Pfizer expands not-for-profit pledge to include more medicines

    The pharma is now committing to providing all of the roughly 500 products in its portfolio, including antibiotics and cancer drugs, to 45 lower-income countries.

    By Kristin Jensen • Jan. 17, 2023
  • Concept image of insulin aspart with fake labeling
    Image attribution tooltip
    Samara Heisz via Getty Images
    Image attribution tooltip

    California files suit against PBMs over insulin prices

    The state filed suit Thursday against pharmacy benefit managers CVS Caremark, Express Scripts and OptumRx, alleging they worked with drugmakers to drive up the price of insulin.

    By Hailey Mensik • Jan. 13, 2023
  • A picture of the exterior of the US Department of Health and Human Services. In front of the building is a black sign designating the building's name.
    Image attribution tooltip
    Alex Wong via Getty Images
    Image attribution tooltip

    HHS lays out timing for drug price negotiations

    The agency will begin discussions on how it will negotiate Medicare drug prices in the spring and publish a list of the first 10 drugs selected by Sept. 1, 2023.

    By • Jan. 11, 2023
  • An up-close and above the shoulder picture of Senator Bernie Sanders wearing a medical face mask
    Image attribution tooltip
    Chip Somodevilla/Getty Images via Getty Images
    Image attribution tooltip

    Sanders to target healthcare costs as leader of influential Senate committee

    The longtime congressman and “Medicare for All” proponent will soon assume leadership of the Senate HELP committee, giving him sway in one of the nation’s most broadly influential health policy forums.

    By Sydney Halleman • Jan. 9, 2023
  • Vials of Eisai and Biogen's new Alzheimer's drug Leqembi
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip
    New Alzheimer's drugs

    Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy

    The pharma set the average annual cost of it and Biogen’s newly approved medicine Leqembi to $26,500, below the cost of the companies’ earlier drug Aduhelm but above one estimate of cost effectiveness.

    By • Jan. 6, 2023
  • Black and white capsule pills on three 20 dollar bills.
    Image attribution tooltip
    Flickr; Images Money
    Image attribution tooltip

    Pharma companies boost drug prices to start year, but hikes lag inflation

    Analysts noted hundreds of list price increases, including dozens by Pfizer. Many checked in around 5%, roughly in line with hikes taken in recent years.

    By • Jan. 3, 2023
  • A Bluebird bio employee works at a laboratory.
    Image attribution tooltip
    Permission granted by Bluebird bio
    Image attribution tooltip

    Gene therapy approval won, Bluebird takes on next challenge: selling it

    The biotech is still waiting to treat its first commercial patient with Zynteglo, but says it has not seen insurers deny coverage for the beta thalassemia drug.

    By • Dec. 12, 2022
  • Three scientists in lab coats look at something at a work table.
    Image attribution tooltip
    Hinterhaus Productions via Getty Images
    Image attribution tooltip
    Sponsored by First Republic Bank

    Life science investment outlook: thinking beyond the pandemic

    Learn about the investment landscape for life science companies, heading into 2023.

    Dec. 12, 2022
  • A picture from chest-up of Bernie Sanders speaking to reporters. The top of the US capitol building is visible behind him.
    Image attribution tooltip
    Anna Moneymaker/Getty Images via Getty Images
    Image attribution tooltip

    Sanders poised to lead Senate health committee

    The longtime pharma critic is set to become chair of the HELP Committee, a post that holds significant power in directing congressional efforts on healthcare issues.

    By Susan Kelly • Nov. 28, 2022
  • A building with logo of drugmaker Eli Lilly.
    Image attribution tooltip
    Eli Lilly & Co.
    Image attribution tooltip

    FDA approves Rezvoglar as second ‘interchangeable’ insulin biosimilar

    Eli Lilly’s long-acting copycat drug, first approved in late 2021, now has a designation that will allow pharmacists to swap it for Sanofi’s Lantus.

    By • Nov. 18, 2022
  • Xavier Becerra sits on a couch onstage at HLTH.
    Image attribution tooltip
    Rebecca Pifer/BioPharma Dive
    Image attribution tooltip

    Divided Congress after midterms will allow HHS to execute on policy priorities, Becerra says

    The agency is focused on implementing drug price negotiation in Medicare and surprise billing regulations, according to the secretary.

    By Rebecca Pifer • Nov. 16, 2022
  • Alexis Borisy and Melanie Nallicheri of EQRx, at launch
    Image attribution tooltip
    Courtesy of EQRx
    Image attribution tooltip

    EQRx redraws ‘radical’ drug pricing plans for first two drugs

    The buzzy startup, which planned to undercut big pharma on price, also dropped plans to seek U.S. approval in lung cancer of an immunotherapy competitor to Keytruda.

    By • Nov. 10, 2022